Cidofovir diphosphate tri(triethylamine), an active intracellular metabolite of Cidofovir, is a selective inhibitor of viral DNA polymerases with Ki values of 6.6, 0.86 and 1.4 μM for HCMV, HSV-1 and HSV-2 DNA polymerase, respectively. Cidofovir (CDV) is a broad-spectrum antiviral agent that has been approved for clinical use in the treatment of cytomegalovirus retinitis. It has also been used off label to treat a variety of other viral infections, including those caused by orf and molluscum contagiosum poxviruses. Because it is a dCMP analog, CDV is thought to act by inhibiting viral DNA polymerases.
Physicochemical Properties
| Molecular Formula | C26H61N6O12P3 |
| Molecular Weight | 742.72 |
| Related CAS # | Cidofovir diphosphate;142276-31-1 |
| Appearance | White to off-white solid powder |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | HCMV, HSV-1, HSV-2, human α, human β, and human γ DNA polymerase are all inhibited by cidofovir diphosphate tritriethylamine (0-1000 μM), with corresponding Ki values of 6.6, 0.86, 1.4, 51, 520, and 300 μM[1]. The vaccinia virus DNA polymerase has a Km value of 23 μM and is inhibited by cidofovir diphosphate tritriethylamine (0.3-30 μM)[2]. |
| References |
[1]. Cidofovir, a New Agent with Potent Anti-Herpesvirus Activity. 1996. [2]. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother. 2005 Aug;49(8):3153-62. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Solubility in Formulation 1: 12.5 mg/mL (16.83 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3464 mL | 6.7320 mL | 13.4640 mL | |
| 5 mM | 0.2693 mL | 1.3464 mL | 2.6928 mL | |
| 10 mM | 0.1346 mL | 0.6732 mL | 1.3464 mL |